

\*  
FILE 'USPAT' ENTERED AT 13:53:35 ON 18 FEB 97  
\*  
\* W E L C O M E T O T H E \*  
\* U. S. P A T E N T T E X T F I L E \*  
\* \*

=> s (prostate) (P) (vaccin?)

2253 PROSTATE

6318 VACCIN?

L1 14 (PROSTATE) (P) (VACCIN?)

=> d 11 1-14

1. 5,498,538, Mar. 12, 1996, Totally synthetic affinity reagents; Brian K. Kay, et al., 435/69.1, 69.7, 172.3; 536/23.4 [IMAGE AVAILABLE]

2. 5,484,592, Jan. 16, 1996, Peptide, immunogenic composition and vaccine or medicinal preparation: a method of immunising a mammal against LHRH, and a method of improving the meat quality of pigs; Robert H. Meloen, et al., 424/185.1, 192.1, 195.11, 198.1; 530/313 [IMAGE AVAILABLE]

3. 5,314,996, May 24, 1994, Isolated nucleotide sequences encoding an antigen binding site of monoclonal antibody PD41; and antigen associated with prostate adenocarcinomas; George L. Wright, Jr., 530/387.3; 435/70.21, 172.2, 240.27; 530/350, 387.1, 388.15, 388.22, 388.8, 395; 536/23.5, 23.53 [IMAGE AVAILABLE]

4. 5,284,133, Feb. 8, 1994, Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means; James S. Burns, et al., 128/200.23, 200.14, 200.24, 202.22, 203.14, 203.15, 203.24; 222/23, 635, 649 [IMAGE AVAILABLE]

5. 5,227,471, Jul. 13, 1993, Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma; George L. Wright, Jr., 530/388.8; 435/70.21, 172.2, 240.27; 530/388.15 [IMAGE AVAILABLE]

6. 5,208,022, May 4, 1993, Non-malignant cells coupled to adjuvants and their use in a method to induce anti-tumor immunity; Arnold E. Eggers, 424/194.1, 184.1, 193.1, 278.1, 279.1, 282.1; 435/240.1; 512/2; 530/402, 403, 404, 405, 406 [IMAGE AVAILABLE]

7. 5,194,384, Mar. 16, 1993, Method for preparing human meloma vaccine; Jean-Claude Bystryn, 424/277.1; 435/240.2, 243; 530/412 [IMAGE AVAILABLE]

8. 5,030,621, Jul. 9, 1991, Shed melanoma antigen compositions; Jean-Claude Bystryn, 424/277.1; 435/71.1, 240.2, 240.3; 514/2, 8, 21; 530/350, 388.85, 389.7, 395, 806, 808, 828 [IMAGE AVAILABLE]

9. RE 33,405, Oct. 23, 1990, Purified human prostate antigen; Tsann M. Chu, et al., 435/7.23, 7.92, 172.2, 188, 240.27; 436/536, 538, 542; 530/350, 380, 388.2, 388.85, 389.7, 391.1, 391.3, 395, 808, 809, 821, 850, 864 [IMAGE AVAILABLE]

10. 4,608,251, Aug. 26, 1986, LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues; Abdus S. Mia, 424/185.1, 195.11, 198.1, 811; 514/19, 800; 530/313, 328; 930/20, 130, DIG.690 [IMAGE AVAILABLE]

11. 4,446,122, May 1, 1984, Purified human prostate antigen; Tsann M. Chu, et al., 435/7.23, 4, 7.92, 240.27, 961, 962; 436/516, 518, 536, 539, 542, 543, 547, 548 [IMAGE AVAILABLE]

12. 4,415,553, Nov. 15, 1983, Compositions, processes for their preparation and method for treatment of neoplasms; Harry P. Zhabilov, et al., 424/277.1; 435/68.1, 70.3, 70.4, 240.1; 514/7, 44; 530/358, 404, 806, 808, 828; 935/3, 10, 19, 65 [IMAGE AVAILABLE]

13. 4,226,747, Oct. 7, 1980, Immunological diagnostic reagents comprising thio-amine terminated latex particles; Gaetano Roncari, 523/201; 435/180, 181, 182; 436/534, 823; 524/458, 498; 525/54.1, 291 [IMAGE AVAILABLE]

14. 4,181,636, Jan. 1, 1980, Process for producing immunological diagnostic reagents; Ernst A. Fischer, 525/54.1; 435/181; 436/823; 525/54.2 [IMAGE AVAILABLE]

=> d 11 1-14 kwic

US PAT NO: 5,498,538 [IMAGE AVAILABLE]

L1: 1 of 14

DETDESC:

DETD (230)

Based . . . the 7E11-C5 antigen and may also be useful to prepare mimetopes of such epitope useful, for example, in preparing a \*\*vaccine\*\* against \*\*prostate\*\* cancer for patients undergoing prostatectomy or post-prostatectomy since the relevant antigen is highly restricted to prostatic carcinoma and normal \*\*prostate\*\*.

US PAT NO: 5,484,592 [IMAGE AVAILABLE]

L1: 2 of 14

SUMMARY:

BSUM(6)

It is known that the LHRH, if coupled to a carrier protein, can be used to \*\*vaccinate\*\* mammals. Such a \*\*vaccination\*\* can be carried out for different reasons which are all connected with the natural function of the LHRH. . . dogs and restlessness in steer fattening. In human health care, immunisation against LHRH can be used in the treatment of \*\*prostate\*\* cancer and breast cancer and, if required, in the treatment of some forms of hypophyseal carcinoma.

SUMMARY:

BSUM(26)

The invention further provides a method of immunising a mammal against LHRH, which method is characterised in that said mammal is \*\*vaccinated\*\* with such a \*\*vaccine\*\* or medicinal preparation according to the invention. Reasons for such a \*\*vaccination\*\* have already been indicated above, such as the use in human medicine for the treatment of \*\*prostate\*\* cancer and breast cancer and of some forms of hypophyseal carcinoma, various uses in veterinary medicine and various used in. . . the scope of a method of improving the meat quality of pigs, which is

characterised in that said pigs are \*\*vaccinated\*\* with such a \*\*vaccine\*\* preparation according to the invention.

US PAT NO: 5,314,996 [IMAGE AVAILABLE]

L1: 3 of 14

DETDESC:

DETD(48)

In another embodiment of the invention, the PMA may be used to prepare a \*\*vaccine\*\* formulation for \*\*prostate\*\* carcinoma. Either purified native PMA (see. Kaufman et al., 1991, Int. J. Can. 48:900-907) or the nucleotide sequence encoding PMA inserted into a virus vector such as \*\*vaccinia\*\* virus (see. Moss., 1991, Sci. 252:1662-1667) can serve as the immunogen for the \*\*vaccine\*\* formulation of this embodiment.

US PAT NO: 5,284,133 [IMAGE AVAILABLE]

L1: 4 of 14

DETDESC:

DETD(3)

A . . . (8) contraceptives such as norethindrone/ethinyl estradiol, norgesterol/ethinyl estradiol, and estrogen (can also be used to treat menopause and osteoporosis), (9) \*\*vaccines\*\* such as zidovudine and other HIV \*\*vaccines\*\* for AIDS, hepatitis B \*\*vaccine\*\*, herpes, malaria, measles, influenza, parainfluenza, adenovirus, rhinovirus, pertussis, and respiratory syncytial virus \*\*vaccines\*\*, (10) antiparasitic drugs such as pentamidine, (11) antiviral drugs such as acyclovir, azidothymidine, ganciclovor, enviroxime, ribavarin, rimantadine, and amantadine, (12). . . from Cutter Biological for treating pseudomonas infections and clinical sepsis, those available from Cytogen for treating ovarian, gastrointestinal, colorectal, and \*\*prostate\*\* cancers, those available from Lilly/Hybritech for treating various cancers, those available from Genetics Institute/NeoRx for treating colorectal cancer, those available. . .

US PAT NO: 5,227,471 [IMAGE AVAILABLE]

L1: 5 of 14

DETDESC:

DETD(49)

In another embodiment of the invention, the PMA may be used to prepare a \*\*vaccine\*\* formulation for \*\*prostate\*\* carcinoma. Either purified native PMA (see, Kaufman et al., 1991, Int. J. Can. 48:900-907) or the nucleotide sequence encoding PMA inserted into a virus vector such as \*\*vaccinia\*\* virus (see. Moss., 1991, Sci. 252:1662-1667) can serve as the immunogen for the \*\*vaccine\*\* formulation of this embodiment.

US PAT NO: 5,208,022 [IMAGE AVAILABLE]

L1: 6 of 14

SUMMARY:

BSUM(39)

A problem with using tumor cells to prepare a \*\*vaccine\*\* is that most human tumors cannot be grown in tissue culture. For example, most common

human tumors, such as colon, breast, non-oat cell of the lung and \*\*prostate\*\* are difficult to grow in sufficient quantities to prepare enough for a single injection.

US PAT NO: 5,194,384 [IMAGE AVAILABLE]

L1: 7 of 14

DETDESC:

DETD (52)

The administration of a cancer \*\*vaccine\*\* prepared in accordance with this invention, is generally applicable to the prevention or treatment of cancer. Cancers which could be. . . accordance with the practices of this invention include cancers of the lung, breast, ovary, cervix, colon, head and neck, pancreas, \*\*prostate\*\*, stomach, bladder, kidney, bone liver, esophagus, brain, testicle, uterus and the various leukemias and lymphomas.

US PAT NO: 5,030,621 [IMAGE AVAILABLE]

L1: 8 of 14

DETDESC:

DETD (52)

The administration of a cancer \*\*vaccine\*\* prepared in accordance with this invention, is generally applicable to the prevention or treatment of cancer. Cancers which could be. . . accordance with the practices of this invention include cancers of the lung, breast, ovary, cervix, colon, head and neck, pancreas, \*\*prostate\*\*, stomach, bladder, kidney, bone liver, esophagus, brain, testicle, uterus and the various leukemias and lymphomas.

US PAT NO: RE 33,405 [IMAGE AVAILABLE]

L1: 9 of 14

SUMMARY:

BSUM(25)

According to the present invention, antigenic preparations from either normal or cancerous human \*\*prostate\*\* tissue, prostatic fluid, cultured human prostatic malignant cells or their media are purified to obtain a preparation consisting essentially of a human \*\*prostate\*\* antigen free of prostatic acid phosphatase. These antigenic preparations are employed for immunological \*\*vaccination\*\* and diagnostic procedures, particularly for immunoprecipitin testing.

SUMMARY:

BSUM(39)

For the preparation of immunogens suitable for preparing diagnostic antibodies against the human \*\*prostate\*\* antigen, conventional \*\*vaccine\*\* preparation techniques can be used. Preferably a non-antigenic adjuvant, e.g. alum, Freund's complete adjuvant, saponin, a quaternary ammonium surfactant, an alkyl amine, etc. is admixed with the purified \*\*prostate\*\* antigen in a suitable immunologically acceptable, non-antigenic carrier and the resultant mixture can be sterilized, e.g. by filtration.

SUMMARY:

BSUM(40)

The \*\*vaccine\*\* can be administered parenterally following regimens already known for immunization with other proteins to stimulate the formation of immunoprecipitating antibodies, . . . well known to those skilled in the art of immunochemistry, and provide a useful reagent for the immunological detection of \*\*prostate\*\* specific antigen in a variety of immunochemical procedures, e.g., immunoprecipitin, fluorescent antibody, serum neutralization, etc. Such antibodies are useful as. . .

US PAT NO: 4,608,251 [IMAGE AVAILABLE]

L1: 10 of 14

SUMMARY:

BSUM(10)

The invention comprises an immunogenic \*\*vaccine\*\* which contains the nonapeptide Lys-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH<sub>sub.2</sub> or the decapeptide Cys-Lys-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH<sub>sub.2</sub>. When administered to a mammal, the \*\*vaccine\*\* induces in vivo production of antibodies to the host's LHRH whereby the natural secretion of LHRH is neutralized. The \*\*vaccine\*\* can be used to immunize the mammal against conception or any other conditions which are directly or indirectly influenced by secretion of LHRH. For example, the \*\*vaccine\*\* can be used in the treatment of \*\*prostate\*\* cancer in men.

SUMMARY:

BSUM(23)

The \*\*vaccine\*\* of the invention, as described above, may be used to treat any condition in man or other mammals which is brought on or aggravated by LHRH. The \*\*vaccine\*\* is thus an effective contraceptive agent in males and females, an agent to treat sexual hyperactivity in males and females, . . . horses, and the treatment of cancers and other conditions which are stimulated by sexual hormones. For example, cancer of the \*\*prostate\*\* gland is believed to be advanced by male hormones and removal of male gonads or injection of antagonistic female hormones is often used for treatment. The anti-LHRH \*\*vaccine\*\* of the invention may be used to treat \*\*prostate\*\* cancer by preventing LHRH from signaling the secretion of male hormones.

US PAT NO: 4,446,122 [IMAGE AVAILABLE]

L1: 11 of 14

SUMMARY:

BSUM(25)

According to the present invention, antigenic preparations from either normal or cancerous human \*\*prostate\*\* tissue, prostatic fluid, cultured human prostatic malignant cells or their media are purified to obtain a preparation consisting essentially of a human \*\*prostate\*\* antigen free of prostatic acid phosphatase. These antigenic preparations are employed for immunological \*\*vaccination\*\* and diagnostic procedures, particularly for immunoprecipitin testing.

SUMMARY:

BSUM(39)

For the preparation of immunogens suitable for preparing diagnostic antibodies against the human \*\*prostate\*\* antigen, conventional \*\*vaccine\*\* preparation techniques can be used. Preferably a non-antigenic adjuvant, e.g. alum, Freund's complete adjuvant, saponin, a quaternary ammonium surfactant, an alkyl amine, etc. is admixed with the purified \*\*prostate\*\* antigen in a suitable immunologically acceptable, non-antigenic carrier and the resultant mixture can be sterilized, e.g. by filtration.

SUMMARY:

BSUM(40)

The \*\*vaccine\*\* can be administered parenterally following regimens already known for immunization with other proteins to stimulate the formation of immunoprecipitating antibodies, . . . well known to those skilled in the art of immunochemistry, and provide a useful reagent for the immunological detection of \*\*prostate\*\* specific antigen in a variety of immunochemical procedures, e.g., immunoprecipitin, fluorescent antibody, serum neutralization, etc. Such antibodies are useful as. . .

US PAT NO: 4,415,553 [IMAGE AVAILABLE]

L1: 12 of 14

DETDESC:

DETD(216)

TABLE 16

---

\*\*VACCINE\*\* TREATMENT OF PATIENTS  
WITH METASTATIC OR INOPERABLE CANCERS  
(1974-1979)

CANCERS IDENTIFIED AT  
PATIENT TIME OF INITIAL TREATMENT

INITIAL STATUS  
\*\*VACCINATION\*\*

1979

---

1. Stomach, lymph nodes and liver  
1974 Alive
2. Testicle, \*\*prostate\*\*, lung  
1974 Alive
3. Stomach, peritoneum  
1975 Alive
4. Stomach, peritoneum  
1975 Alive
5. Pancreas, liver 1975. . .  
Mar., '78.sup.1  
Died,  
15th day

13. Astrocytoma (brain)  
                          Mar., '78  
                          Died,  
14. \*\*Prostate\*\*, bone, lung  
                          Aug., '78.sup.2  
                          34th day  
                          Died  
15. Breast, bone (leg, arm)  
                          Apr., '79  
                          30 days  
                          Died, . . .

US PAT NO:       4,226,747 [IMAGE AVAILABLE]

L1: 13 of 14

SUMMARY:

BSTU(14)

papilloma

Influenza A & B  
Fowl pest  
Herpes simplex  
Adenoviruses  
Polyoma  
Rous sarcoma  
\*\*Vaccinia\*\*  
Polio virus  
German measles  
Canine distemper  
Leukaemia  
Mumps  
Newcastle disease (domestic fowl disease)  
Catalases

3. Creatin phosphokinases  
Organ-specific antigens

Kidney  
Liver  
Skin  
Heart (myoglobin)  
Gastrointestinal tract

\*\*Prostate\*\*  
Embryo antigens (e.g. CEA antigen)  
Tumour antigens

4. Connective tissue components  
Muscle  
Collagen  
Amyloid

5. . .

US PAT NO:       4,181,636 [IMAGE AVAILABLE]

L1: 14 of 14

SUMMARY:

BSTU(22)

papilloma

Influenza A & B  
Fowl plaque

Herpes simplex  
Adenoviruses  
Polyema  
Rous sarcoma  
**\*\*Vaccinia\*\***  
Poliovirus  
Measles  
Canine distemper  
Leukemia  
Mumps  
Newcastle disease  
Sendai  
ECHO  
Foot. . .  
Egg ovalbumin  
Ovine serum albumin  
Kidney  
Liver  
Skin  
Heart (Myoglobin)  
Gastrointestinal tract  
**\*\*Prostate\*\***  
Embryonic antigens (alpha 1 fetoprotein)  
Tumor antigens (carcinoembryonic antigen)  
Muscle  
Collagen  
Amyloid  
Hormones

=> d 11 1-4 date

TITLE: Totally synthetic affinity reagents L1: 1 of 14  
US PAT NO: 5,498,538 DATE ISSUED: Mar. 12, 1996  
[IMAGE AVAILABLE]  
APPL-NO: 08/176,500 DATE FILED: Dec. 30, 1993  
REL-US-DATA: Continuation of Ser. No. 13,416, Feb. 1, 1993, abandoned,  
which is a continuation-in-part of Ser. No. 854,133,  
Mar. 19, 1992, abandoned, which is a continuation of  
Ser. No. 480,420, Feb. 15, 1990, abandoned.

TITLE: Peptide, immunogenic composition and vaccine or medicinal preparation: a method of immunising a mammal against LHRH, and a method of improving the meat quality of pigs  
US PAT NO: 5,484,592 DATE ISSUED: Jan. 16, 1996  
[IMAGE AVAILABLE]  
APPL-NO: 08/149,001 DATE FILED: Nov. 8, 1993  
FRN-PR. NO: 8900726 FRN FILED: Mar. 23, 1989  
FRN-PR. CO: Netherlands  
REL-US-DATA: Continuation of Ser. No. 761,849, Sep. 17, 1991,  
abandoned.

TITLE: Isolated nucleotide sequences encoding an antigen binding site of monoclonal antibody PD41; and antigen associated with prostate adenocarcinomas L1: 3 of 14  
US PAT NO: 5,314,996 DATE ISSUED: May 24, 1994

APPL-NO: [IMAGE AVAILABLE]  
REL-US-DATA: 08/091,628 DATE FILED: Jul. 13, 1993  
Division of Ser. No. 828,057, Jan. 30, 1992, Pat. No.  
5,227,471.

TITLE: Inhalation device with a dose-timer, an actuator L1: 4 of 14  
mechanism, and patient compliance monitoring means  
US PAT NO: 5,284,133 DATE ISSUED: Feb. 8, 1994  
[IMAGE AVAILABLE]  
APPL-NO: 07/919,030 DATE FILED: Jul. 23, 1992  
=> s (psa or prostate(w) specific or psma or pap or prostatic) (P)vaccin?  
1941 PSA  
2253 PROSTATE  
785420 SPECIFIC  
14 PSMA  
1471 PAP  
1344 PROSTATIC  
6318 VACCIN?  
L2 8 (PSA OR PROSTATE(W) SPECIFIC OR PSMA OR PAP OR PROSTATIC) (P)  
VAC CIN?  
=> d 12 1-8

1. 5,589,174, Dec. 31, 1996, Anti-human influenza virus antibody; Yoshinobu Okuno, et al., 424/147.1; 435/240.27; 530/387.9, 388.2, 388.3, 389.1, 389.4; 935/103, 104 [IMAGE AVAILABLE]

2. 5,498,538, Mar. 12, 1996, Totally synthetic affinity reagents; Brian K. Kay, et al., 435/69.1, 69.7, 172.3; 536/23.4 [IMAGE AVAILABLE]

3. 5,478,556, Dec. 26, 1995, Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor; Robert L. Elliott, et al., 424/85.2, 85.1, 277.1; 530/351, 828 [IMAGE AVAILABLE]

4. 5,372,943, Dec. 13, 1994, Lipid microemulsions for culture media; Duane Inlow, et al., 435/240.31; 252/302; 428/402.2; 435/240.1, 240.3 [IMAGE AVAILABLE]

5. 5,238,836, Aug. 24, 1993, Plasmodium falciparum merozoite antigen peptides; Ulrich Certa, et al., 435/252.3, 69.3, 172.3, 235.1, 252.33, 258.2, 320.1; 530/350; 536/23.5; 935/12, 29, 41, 56, 65, 72 [IMAGE AVAILABLE]

6. 5,024,947, Jun. 18, 1991, Serum free media for the growth on insect cells and expression of products thereby; Duane Inlow, et al., 435/240.31, 70.1, 240.1, 240.2, 240.3 [IMAGE AVAILABLE]

7. RE 33,405, Oct. 23, 1990, Purified human prostate antigen; Tsann M. Chu, et al., 435/7.23, 7.92, 172.2, 188, 240.27; 436/536, 538, 542, 530/350, 380, 388.2, 388.85, 389.7, 391.1, 391.3, 395, 808, 809, 821, 850, 864 [IMAGE AVAILABLE]

8. 4,446,122, May 1, 1984, Purified human prostate antigen; Tsann M. Chu, et al., 435/7.23, 4, 7.92, 240.27, 961, 962; 436/516, 518, 536, 539, 542, 543, 547, 548 [IMAGE AVAILABLE]  
=> d 12 1-8 kwic

US PAT NO: 5,589,174 [IMAGE AVAILABLE]

L2: 1 of 8

DETDESC:

DETD(99)

The . . . the cells with AI3C (1:1000), rabbit anti-mouse immunoglobulin G serum (1:1000), goat anti-rabbit immnuoglobulin G serum (1:500), and peroxidase-rabbit anti-peroxidase (\*\*PAP\*\*) complex (1:1000). Each treatment was 40 minutes long and was followed by a washing with PBS. The peroxide reaction was. . . molecule of H3N2 subtype influenza viruses, like AI3C type antibody. So this stem region polypeptide is useful for the influenza \*\*vaccine\*\*.

US PAT NO: 5,498,538 [IMAGE AVAILABLE]

L2: 2 of 8

DETDESC:

DETD(230)

Based . . . the 7E11-C5 antigen and may also be useful to prepare mimetopes of such epitope useful, for example, in preparing a \*\*vaccine\*\* against prostate cancer for patients undergoing prostatectomy or post-prostatectomy since the relevant antigen is highly restricted to \*\*prostatic\*\* carcinoma and normal prostate.

US PAT NO: 5,478,556 [IMAGE AVAILABLE]

L2: 3 of 8

DETDESC:

DETD(3)

The "Vaccine" is usually customized for an individual patient; that is, the autologous or allogeneic TAA is mixed with one million colony units of GM-CFS and with ten thousand IU's of IL-2 (see FIG. 2 for details of the formulation of the \*\*vaccine\*\*). A number of other commercially available cancer antigens can also be used in the "Vaccine" in addition to TAA, including carcinoembryonic antigen (CEA), CA 15-3, CA 125, CA 19-9 and prostate specific antigen (\*\*PSA\*\*). The use of these cancer antigens may be used in concert with autologous or allogeneic TAA.

US PAT NO: 5,372,943 [IMAGE AVAILABLE]

L2: 4 of 8

DETDESC:

DETD(46)

Other . . . growth factors, human growth hormone, as well as porcine, bovine and other growth hormones, epidermal growth factor, insulin, hepatitis B \*\*vaccine\*\*, superoxide dismutase, Factor VIII, Factor VIII C, atrial natriuretic factor, feline leukemia virus \*\*vaccines\*\*, as, for example, gp70 polypeptides, the light and heavy chains of antibody molecules, lectins such as Ricin communis agglutinin (RCA), diphtheria toxin, gelonin, exotoxin from Pseudomonas aeruginosa, toxic proteins from Phytolacca americana (PAPI, PAPII and \*\*PAP\*\*-s), insecticidal proteins from Bacillus thuringiensis, many enzymes as for example, CAT, as well as

innumerable other hybrid proteins.

US PAT NO: 5,238,836 [IMAGE AVAILABLE]

L2: 5 of 8

SUMMARY:

BSUM(7)

A protein has been detected on the surface of merozoites and schizonts which could be active as a \*\*vaccine\*\* against malaria. When synthesized, the protein has an apparent molecular weight of 190,000-200,000 D (Perrin et al., Clin. Exp. Immunol. . . [1983] and Mol. Biochem. Parasitol. 11, 61-80 [1984]). It has been called GP185, p190, 195-kD protein and polymorphic schizont antigen (\*\*PSA\*\*). In addition, much, but not all of the protein is lost when merozoites invade new erythrocytes (Holder et al., supra; . . .).

US PAT NO: 5,024,947 [IMAGE AVAILABLE]

L2: 6 of 8

DETDESC:

DETD(64)

According . . . growth factors, human growth hormone, as well as porcine, bovine and other growth hormones, epidermal growth factor, insulin, hepatitis B \*\*vaccine\*\*, superoxide dismutase, Factor VIII, Factor VIII C, atrial natriuretic factor, feline leukemia virus \*\*vaccines\*\*, as, for example, gp70 polypeptides, lectins such as Ricin communis agglutinin (RCA), diphtheria toxin, gelonin, exotoxin from Pseudomonas aeruginosa, toxic proteins from Phytolacca americana (PAPI, PAPII and \*\*PAP\*\*-S), insecticidal proteins from Bacillus thuringiensis, many enzymes as for example, CAT, as well as innumerable other hybrid proteins.

US PAT NO: RE 33,405 [IMAGE AVAILABLE]

L2: 7 of 8

SUMMARY:

BSUM(25)

According to the present invention, antigenic preparations from either normal or cancerous human prostate tissue, \*\*prostatic\*\* fluid, cultured human \*\*prostatic\*\* malignant cells or their media are purified to obtain a preparation consisting essentially of a human prostate antigen free of \*\*prostatic\*\* acid phosphatase. These antigenic preparations are employed for immunological \*\*vaccination\*\* and diagnostic procedures, particularly for immunoprecipitin testing.

SUMMARY:

BSUM(40)

The \*\*vaccine\*\* can be administered parenterally following regimens already known for immunization with other proteins to stimulate the formation of immunoprecipitating antibodies, . . . well known to those skilled in the art of immunochemistry, and provide a useful reagent for the immunological detection of \*\*prostate\*\* \*\*specific\*\* antigen in a variety of immunochemical procedures, e.g., immunoprecipitin, fluorescent

antibody, serum neutralization, etc. Such antibodies are useful as a control reagent in the diagnostic test for \*\*prostatic\*\* cancer described more particularly below.

US PAT NO: 4,446,122 [IMAGE AVAILABLE]

L2: 8 of 8

SUMMARY:

BSUM(25)

According to the present invention, antigenic preparations from either normal or cancerous human prostate tissue, \*\*prostatic\*\* fluid, cultured human \*\*prostatic\*\* malignant cells or their media are purified to obtain a preparation consisting essentially of a human prostate antigen free of \*\*prostatic\*\* acid phosphatase. These antigenic preparations are employed for immunological \*\*vaccination\*\* and diagnostic procedures, particularly for immunoprecipitin testing.

SUMMARY:

BSUM(40)

The \*\*vaccine\*\* can be administered parenterally following regimens already known for immunization with other proteins to stimulate the formation of immunoprecipitating antibodies, . . . well known to those skilled in the art of immunochemistry, and provide a useful reagent for the immunological detection of \*\*prostate\*\* \*\*specific\*\* antigen in a variety of immunochemical procedures, e.g., immunoprecipitin, fluorescent antibody, serum neutralization, etc. Such antibodies are useful as a control reagent in the diagnostic test for \*\*prostatic\*\* cancer described more particularly below.

=> d 12 1-8 date

L2: 1 of 8

TITLE:	Anti-human influenza virus antibody		
US PAT NO:	5,589,174 [IMAGE AVAILABLE]	DATE ISSUED:	Dec. 31, 1996
APPL-NO:	08/229,781	DATE FILED:	Apr. 19, 1994
FRN-PR. NO:	4-272538	FRN FILED:	Sep. 17, 1992
FRN-PR. CO:	Japan		
FRN-PR. NO:	5-115216	FRN FILED:	Apr. 20, 1993
FRN-PR. CO:	Japan		
FRN-PR. NO:	6-070194	FRN FILED:	Mar. 16, 1994
FRN-PR. CO:	Japan		
REL-US-DATA:	Continuation-in-part of Ser. No. 54,016, Apr. 29, 1993, abandoned.		

L2: 2 of 8

TITLE:	Totally synthetic affinity reagents		
US PAT NO:	5,498,538 [IMAGE AVAILABLE]	DATE ISSUED:	Mar. 12, 1996
APPL-NO:	08/176,500	DATE FILED:	Dec. 30, 1993
REL-US-DATA:	Continuation of Ser. No. 13,416, Feb. 1, 1993, abandoned, which is a continuation-in-part of Ser. No. 854,133, Mar. 19, 1992, abandoned, which is a continuation of Ser. No. 480,420, Feb. 15, 1990, abandoned.		

L2: 3 of 8

TITLE: Vaccination of cancer patients using tumor-associated  
 antigens mixed with interleukin-2 and  
 granulocyte-macrophage colony stimulating factor  
 US PAT NO: 5,478,556 DATE ISSUED: Dec. 26, 1995  
 [IMAGE AVAILABLE]  
 APPL-NO: 08/202,516 DATE FILED: Feb. 28, 1994

L2: 4 of 8

TITLE: Lipid microemulsions for culture media  
 US PAT NO: 5,372,943 DATE ISSUED: Dec. 13, 1994  
 [IMAGE AVAILABLE]  
 APPL-NO: 08/090,568 DATE FILED: Jul. 12, 1993  
 REL-US-DATA: Continuation of Ser. No. 829,610, Jan. 30, 1992,  
 abandoned, which is a continuation of Ser. No. 248,830,  
 Sep. 23, 1988, abandoned, which is a  
 continuation-in-part of Ser. No. 77,189, Jul. 24, 1987,  
 abandoned.

L2: 5 of 8

TITLE: Plasmodium falciparum merozoite antigen peptides  
 US PAT NO: 5,238,836 DATE ISSUED: Aug. 24, 1993  
 [IMAGE AVAILABLE]  
 APPL-NO: 07/167,811 DATE FILED: Mar. 14, 1988  
 FRN-PR. NO: 8706599 FRN FILED: Mar. 19, 1987  
 FRN-PR. CO: United Kingdom

L2: 6 of 8

TITLE: Serum free media for the growth on insect cells and  
 expression of products thereby  
 US PAT NO: 5,024,947 DATE ISSUED: Jun. 18, 1991  
 [IMAGE AVAILABLE]  
 APPL-NO: 07/077,303 DATE FILED: Jul. 24, 1987

L2: 7 of 8

TITLE: Purified human prostate antigen  
 US PAT NO: RE 33,405 DATE ISSUED: Oct. 23, 1990  
 [IMAGE AVAILABLE]  
 APPL-NO: 07/254,015 DATE FILED: Oct. 4, 1988  
 REL-US-DATA: Continuation-in-part of Ser. No. 108,217, Dec. 28, 1979,  
 abandoned.

REISSUE OF:

US PAT NO: 4,446,122  
 DATE ISSUED: May 1, 1984  
 APPL-NO: 316,954  
 DATE FILED: Dec. 23, 1980

L2: 8 of 8

TITLE: Purified human prostate antigen  
 US PAT NO: 4,446,122 DATE ISSUED: May 1, 1984  
 [IMAGE AVAILABLE]  
 APPL-NO: 06/316,954 DATE FILED: Aug. 28, 1981  
 PCT-NO: PCT/US80/01708 PCT-FILED: Dec. 23, 1980  
 371-DATE: Aug. 28, 1981  
 102(E)-DATE: Aug. 28, 1981  
 PCT-PUB-NO: WO81/01849 PCT-PUB-DATE: Jul. 9, 1981  
 REL-US-DATA: Continuation-in-part of Ser. No. 108,217, Dec. 28, 1979,  
 abandoned.  
 => s 12 and liposome?

4219 LIPOSOME?

L3            2 L2 AND LIPOSOME?  
=> d 13 1-2

1. 5,372,943, Dec. 13, 1994, Lipid microemulsions for culture media;  
Duane Inlow, et al., 435/240.31; 252/302; 428/402.2; 435/240.1, 240.3  
[IMAGE AVAILABLE]

2. 5,238,836, Aug. 24, 1993, Plasmodium falciparum merozoite antigen  
peptides; Ulrich Certa, et al., 435/252.3, 69.3, 172.3, 235.1, 252.33,  
258.2, 320.1; 530/350; 536/23.5; 935/12, 29, 41, 56, 65, 72 [IMAGE  
AVAILABLE]

=> d 13 1-2 kwic

US PAT NO:        5,372,943 [IMAGE AVAILABLE]

L3: 1 of 2

SUMMARY:

BSUM(6)

Attempts have been described in the literature to supply lipids as  
\*\*liposomes\*\* to cells in culture [N. N. Iscove, Culture of Lymphocytes  
and Hemopoietic Cells in Serum-Free Medium, p. 169-185, in D. . . . D.  
et al., Methods in Cell Biology, 14:43-71 (1976), D. M. Prescott, (ed.)],  
and M. Kriegler, Cell, 33(2):413-422 (1983). These \*\*liposomes\*\* are most  
typically prepared by sonicating the lipid mix in the presence of a  
protein (albumin) and result in particles. . . .

SUMMARY:

BSUM(7)

Iscove, . . . suspending medium containing albumin is then added and  
the mixture is sonicated to disperse the lipids in the form of  
vesicles--\*\*liposomes\*\* small enough to pass through the pores of a  
sterilizing filter (0.45 .mu.m). Iscove's following description of such a  
process. . . .

SUMMARY:

BSUM(9)

The . . . become somewhat more opaque in the first day or two of  
storage. This change probably reflects some coalescence of the  
\*\*liposomes\*\* to larger average size but has no influence on their  
effectiveness in culture . . . .

DETDESC:

DETD(46)

Other . . . growth factors, human growth hormone, as well as porcine,  
bovine and other growth hormones, epidermal growth factor, insulin,  
hepatitis B \*\*vaccine\*\*, superoxide dismutase, Factor VIII, Factor VIII  
C, atrial natriuretic factor, feline leukemia virus \*\*vaccines\*\*, as, for  
example, gp70 polypeptides, the light and heavy chains of antibody  
molecules, lectins such as Ricin communis agglutinin (RCA), diphtheria  
toxin, gelonin, exotoxin from Pseudomonas aeruginosa, toxic proteins from  
Phytolacca americana (PAPI, PAPII and \*\*PAP\*\*-s), insecticidal proteins

from *Bacillus thuringiensis*, many enzymes as for example, CAT, as well as innumerable other hybrid proteins.

US PAT NO: 5,238,836 [IMAGE AVAILABLE]

L3: 2 of 2

SUMMARY:

BSUM(7)

A protein has been detected on the surface of merozoites and schizonts which could be active as a \*\*vaccine\*\* against malaria. When synthesized, the protein has an apparent molecular weight of 190,000-200,000 D (Perrin et al., Clin. Exp. Immunol.. . . [1983] and Mol. Biochem. Parasitol. 11, 61-80 [1984]). It has been called GP185, p190, 195-kD protein and polymorphic schizont antigen (\*\*PSA\*\*). In addition, much, but not all of the protein is lost when merozoites invade new erythrocytes (Holder et al., supra; . . .

DETDESC:

DETD(39)

Suitable . . . muramyl dipeptide, dimethylglycine, tuftsin and oil emulsions. The polypeptide of the present invention can also be administered following incorporation into \*\*liposomes\*\* or other micro-carriers, or after conjugation to polysaccharides, other proteins or other polymers or in combination with Quil-A to form. . . .  
=>